Analysts Offer Insights on Healthcare Companies: Alimera (NASDAQ: ALIM) and Zynex Inc (NASDAQ: ZYXI)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alimera (ALIMResearch Report) and Zynex Inc (ZYXIResearch Report) with bullish sentiments.

Alimera (ALIM)

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Alimera yesterday and set a price target of $2.00. The company’s shares closed last Monday at $0.34, close to its 52-week low of $0.32.

According to TipRanks.com, D’silva is a 1-star analyst with an average return of -1.9% and a 35.0% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, EyePoint Pharmaceuticals Inc, and Eton Pharmaceuticals Inc.

Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $1.75.

See today’s analyst top recommended stocks >>

Zynex Inc (ZYXI)

In a report released today, Marc Wiesenberger from B.Riley FBR reiterated a Buy rating on Zynex Inc, with a price target of $12.00. The company’s shares closed last Monday at $9.54.

Wiesenberger has an average return of 88.2% when recommending Zynex Inc.

According to TipRanks.com, Wiesenberger is ranked #513 out of 5580 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zynex Inc with a $12.00 average price target, representing a 22.3% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.